Weizhi Jun has developed pipelines in oncology, neuroscience, digestive, and immune diseases, covering all mainstream drug formats, including probiotic strains, genetically engineered microbes, microbial metabolites, and fecal microbiota transplantation.
Weizhi Jun integrates resources from leading pharmaceutical companies, health enterprises, top universities, research institutions, and key hospitals to drive innovation and commercial partnerships, building an industry ecosystem.
Weizhi Jun combines AI and data-driven approaches to build an AI+biotechnology microbiome research and product development platform, enabling high-quality data analysis, accumulation, and output to continuously incubate high-quality microbiome drug pipelines and products.
Weizhi Jun emphasizes a pragmatic, win-win talent philosophy and a diverse talent management system, fostering an innovative, inclusive, and equal work environment to accelerate employee growth and collaborate with top global microbiome pharmaceutical talent.
Weizhi Jun is a leading AI-driven microbiome research and industrialization platform in China, using microbiome-based therapies like probiotic strains and genetically engineered microbes to address gastrointestinal and systemic diseases. It integrates AI with gut microbiome technology to improve drug development efficiency and success rates, while offering fecal microbiota transplantation solutions, probiotic products, and industry applications.
